CRISPR Therapeutics AGCRSPNASDAQ
LOADING
|||
R&D Expense Growth Under Pressure
Below historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
-17.21%
↓ 114% below average
Average (9y)
123.23%
Historical baseline
Range
High:731.00%
Low:-17.21%
CAGR
NaN%
Modest growth trend
| Period | Value |
|---|---|
| 2024 | -17.21% |
| 2023 | -16.10% |
| 2022 | 35.55% |
| 2021 | 53.84% |
| 2020 | 23.43% |
| 2019 | 57.65% |
| 2018 | 63.00% |
| 2017 | 65.25% |
| 2016 | 235.94% |
| 2015 | 731.00% |